CDK9/CyclinT Kinase Assay Kit
The CDK9/CyclinT Kinase Assay Kit is designed to measure CDK9/CyclinT kinase activity for screening and profiling applications using Kinase-Glo™ Max as a detection reagent. The assay kit comes in a convenient 96-well or 384-well format, with enough purified recombinant CDK9/CyclinT kinase, kinase substrate, ATP, and kinase assay buffer for 100 or 400 enzyme reactions.
This product has been cited 8 times.
- Kinase-Glo MAX (Promega #V6071)
- DTT (Dithiothreitol), 1M, optional
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- 30°C incubator
96 reactions
| Catalog # | Component | Amount | Storage |
| 40307 | CDK9/CyclinT, GST-Tag* | 10 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 100 µl | -20°C |
| 79604 | 5x CDK substrate peptide 2 | 1 ml | -20°C |
| 79696 | 96-well plate, white | 1 | Room temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
384 reactions
| Catalog # | Component | Amount | Storage |
| 40307 | CDK9/CyclinT, GST-Tag* | 2 x 10 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 2 x 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 200 µl | -20°C |
| 79604 | 5x CDK substrate peptide 2 | 2 x 1 ml | -20°C |
| 79969 | White, 384-well plate | 1 | Room temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
Cyclin-dependent kinase 9 (CDK9) is the catalytic subunit of the positive transcription elongation factor b (P-TEFb) complex, which phosphorylates the C-terminal domain of RNA polymerase II, a key player in the production of mature RNA. P-TEFb also includes cyclinT. CDK9 translocates to the nucleus once it gets auto phosphorylated, where it can associate with cyclinT. Hyperactivation of cyclins is known to result in cancer and the development of resistance to therapy, and CDK9-cyclinT is involved in the transcription of oncogenes. The inhibition or degradation of specific CDK-cyclin complexes could prove beneficial in cancer treatment, but the development of specific inhibitors has been difficult. Recently a small molecule degrader specific for CDK9-cyclinT was identified, LL-K9-3, which resulted in lower levels of androgen receptor (AR) and cMyc in 22RV1 cells. LL-K9-3 thus seemed more effective than SNS032, its parental CDK9 inhibitor, and the CDK9 PROTAC Thal-SNS032. Further research into new and more specific degrader molecules will prove beneficial for cancer therapy.
Napolitano G, et al., 2003 J Cell Physiol. 197(1):1-7.
Li J., et al., 2022 J Med Chem. 65(16):11034-11057.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.